Avastin gains further support

Article

Avastin (bevacizumab) is effective in the arrest of angiogenesis at several stages, according to a study published online ahead of print by Acta Ophthalmologica.

Avastin (bevacizumab) is effective in the arrest of angiogenesis at several stages, according to a study published online ahead of print by Acta Ophthalmologica.

Raquel Soares MSc, PhD of the Department of Biochemistry in the Faculty of Medicine, University of Porto, Portugal and colleagues examined the effect of bevacizumab on neovascularization at every stage throughout the process by injecting clinically established doses of bevacizumab into human umbilical vein endothelial cells (HUVECs). The team then monitored cell cytotoxicity, proliferation, apoptosis, migration and vessel assembly, both in vitro and in a rodent model.

The researchers found that the presence of bevacizumab did not induce cytotoxicity; proliferation, migration capacity and the assembly of capillary-like structures were significantly reduced, and the rate of apoptosis was significantly increased, following the injection of bevacizumab.

Thus the team concluded that bevacizumab intervenes at several stages of the angiogenic process to halt further progression, and that bevacizumab's indication as an anti-angiogenic is justified.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.